Division of Gilead Sciences Inc.
Latest From EpiTherapeutics APS
With much of its cash held ex-US, Gilead is unlikely to undertake another large acquisition soon, even if there are logical reasons to bolster its NASH pipeline or try to acquire partner Galapagos. Firm is likely to follow Kite buyout with targeted cancer deals.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
Martin Bonde, CEO
Henrik Blou, Dir., Bus. Dev.
Lars-Ole Gerlach, EVP, R&D
- Contact Info
Phone: (45) 2025 3560
Ole Maaløesvej 3
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.